Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (807)	9/18/1998 8:22:00 AM
From: Wally	Read Replies (3) \| Respond to of 998

Arnie: There may be an ongoing symbiosis between Chiron & Cephalon. Their dissimilarities may have been the draw with Myotrophin. Each company had its own strength to have created that allegiance in the first place. I would just be guessing if I speculated on the possibility of Chiron buying Cephalon. My guess is that Cephalon has something to offer, and if they can't go it alone, who knows their strengths better than Chiron? So yes, on the surface it would seem very possible. It still comes down to whether or not symbiosis exists beyond Myotrophin. Also, neither company has stood still. Other relationships and other pressing interests may now effect any chance of Chiron being willing or able to buy Cephalon. I think you're very correct about Cephalon and other bio-techs being dirt cheap. They've probably been hit harder than any other sector. If they're interested, the attractive price would certainly play into Chiron's decision. Regards, Wally